Life Expectancy with Type 2 Diabetes: What the Research Actually Shows

Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional about your individual health situation, treatment options, and management goals.

“How long will I live with type 2 diabetes?” is one of the first questions many people ask after a diagnosis — and one of the most difficult to answer honestly.

The answer the evidence gives is this: type 2 diabetes is associated with a real reduction in life expectancy. On average, it shortens life by 6–10 years depending on age at diagnosis and how the condition is managed. But these are averages, and averages hide enormous variation. The reduction in life expectancy is not fixed. It depends heavily on four modifiable factors — blood glucose, blood pressure, weight, and cholesterol — that are within your control to change.

This article presents the actual research on life expectancy and type 2 diabetes, including the numbers by age of diagnosis, what the science says about the factors that matter most, and how much you can realistically improve your own outlook through management.

At a Glance: Life Expectancy and Type 2 Diabetes

Age at DiagnosisEstimated Life Expectancy ReductionKey Source Age 30Up to 14 yearsLancet Diabetes & Endocrinology, 2023 Age 40Approximately 10 yearsLancet Diabetes & Endocrinology, 2023 Age 50Approximately 6 yearsCDC / JAMA Network Open, 2022 Age 60Approximately 3–4 yearsUKPDS Outcomes Model; Lancet 2023 With optimal managementCan recover 3–10+ yearsCDC / JAMA Network Open, 2022

These are population averages. Individual outcomes depend significantly on management, complications, and other health factors.

The Real Numbers: How Much Does Type 2 Diabetes Reduce Life Expectancy?

The most frequently cited figure comes from the CDC, drawing on a major 2022 study in JAMA Network Open: at age 50, life expectancy is approximately 6 years shorter for people with type 2 diabetes compared with those without diabetes (Source: Kianmehr H, et al., JAMA Network Open, 2022).

But the picture is more complex than a single number. A landmark 2023 study published in The Lancet Diabetes & Endocrinology — analysing 23 million person-years of data across high-income countries including the US, UK, Canada, and Australia — found that the impact on life expectancy depends strongly on age at diagnosis:

• Diagnosed at age 30: up to 14 years less life expectancy
• Diagnosed at age 40: approximately 10 years less
• Diagnosed at age 50: approximately 6 years less
• Diagnosed at age 60: approximately 3–4 years less

The study also found that every decade of earlier diagnosis was associated with approximately 3–4 additional years of life expectancy reduction (Source: Emerging Risk Factors Collaboration, Lancet Diabetes & Endocrinology, 2023).

The UKPDS Outcomes Model — one of the longest-running diabetes studies in history — adds context on individual variation: diabetic men aged 55 were predicted to live 3.6 to 11.5 years less than the general population, depending on their individual risk profile (Source: Stevens RJ, et al., PMC, 2009). The wide range illustrates that the “average” masks enormous individual variation.

Why Age at Diagnosis Matters So Much

The reason earlier diagnosis carries a larger life expectancy reduction is not that younger people with diabetes are more severely affected in any single year — it is that they spend more years living with the cumulative effects of elevated blood glucose on blood vessels, nerves, and organs.

Diabetes damages the cardiovascular system, kidneys, eyes, and nerves progressively over time. A person diagnosed at 30 who manages their condition reasonably but not optimally may spend 30–40 years accumulating microvascular and macrovascular damage that a person diagnosed at 60 has far less time to accumulate.

This is also why the research emphasises that an early diagnosis, caught before significant complications develop, combined with aggressive management from the outset, can substantially reduce the gap between predicted and actual outcomes.

If you are newly diagnosed, our guide on what to do first after a type 2 diabetes diagnosis and understanding what your HbA1c number means are the essential first steps.

The Four Factors That Determine How Long You Live

The most actionable research on this topic comes from the 2022 study in JAMA Network Open by Kianmehr and colleagues, which the CDC has highlighted as a landmark finding. The study identified four treatment goals and measured how meeting each one changes life expectancy:

1. Weight (BMI)
2. Blood glucose (HbA1c)
3. Blood pressure (systolic)
4. LDL cholesterol

The findings are striking. For the average person with type 2 diabetes, managing all four factors to target can increase life expectancy by 3 years. For people with the highest levels of all four risk factors, meeting targets may increase life expectancy by more than 10 years (Source: CDC, citing Kianmehr et al., 2022).

Of the four, BMI reduction was associated with the greatest life expectancy gain, followed by HbA1c reduction. This makes weight management the single most impactful modifiable target in terms of longevity — a finding that has significant implications for treatment priorities.

Blood Glucose (HbA1c) Control and Longevity

HbA1c measures your average blood glucose over the past 3 months. The HbA1c target for most people with type 2 diabetes is below 7% (53 mmol/mol) according to the ADA, and below 48 mmol/mol (6.5%) in the UK’s NICE guidelines.

Research quantifies what improving HbA1c actually means for longevity:

• A study from the University of Florida found that improving HbA1c from 9.9% to a normal level was associated with a 3.8-year increase in life expectancy (Source: UF Health, 2022)
• The landmark UKPDS trial showed that intensive glucose control reduced microvascular complications (kidney disease, eye disease, nerve damage) by 25% over 10 years, and this benefit persisted long after the trial ended — an effect known as “metabolic memory” (Source: UKPDS Group, The Lancet, 1998)

The mechanism: persistently high blood glucose damages small blood vessels (microvascular damage) and accelerates atherosclerosis in large blood vessels (macrovascular damage). Both pathways ultimately shorten life through kidney failure, heart attack, and stroke.

For strategies to improve your HbA1c without medication, see our guide on how to lower A1c naturally. Diet is also a central pillar — the best foods for blood sugar control and an insulin resistance diet both directly support better HbA1c outcomes.

Blood Pressure and Cholesterol: The Cardiovascular Connection

Cardiovascular disease is the leading cause of death in people with type 2 diabetes, accounting for approximately 50–80% of deaths in large cohorts (Source: Emerging Risk Factors Collaboration, The Lancet, 2011). This is why blood pressure and cholesterol control are not peripheral concerns — they are central to longevity.

Blood pressure targets: The American Diabetes Association’s 2024 Standards of Care recommend a target of below 130/80 mmHg for most people with type 2 diabetes. Every 10 mmHg reduction in systolic blood pressure is associated with a significant reduction in cardiovascular events, stroke, and mortality.

Cholesterol targets: For people with type 2 diabetes at high cardiovascular risk, the ADA recommends LDL cholesterol below 70 mg/dL (1.8 mmol/L). The UKPDS showed that lipid-lowering treatment reduced coronary events by approximately 20–30% in people with diabetes (Source: UKPDS Group, BMJ, 1998).

The important message: even if your blood glucose is well-controlled, uncontrolled blood pressure and elevated LDL significantly shorten life expectancy in T2D. These are not separate problems — they are part of the same cardiovascular risk profile that determines longevity.

Weight Loss: The Single Biggest Modifiable Factor

The CDC finding that BMI reduction adds more life expectancy than any other single target is supported by other lines of evidence.

The DiRECT trial (UK and Scotland) showed that 46% of participants who achieved 15 kg or more of weight loss entered type 2 diabetes remission at 1 year — with sustained benefits at 5 years (Source: Lean MEJ, et al., The Lancet, 2018; Diabetes Care, 2022). Remission means blood glucose returning to normal ranges without medication, which removes many of the mechanisms that shorten life.

Even without remission, a 5–10% reduction in body weight significantly improves HbA1c, blood pressure, and LDL cholesterol simultaneously — making it a lever that moves all four CDC treatment goal targets at once.

The benefit of weight loss must be sustained to preserve the life expectancy gain. Long-term approaches — dietary changes, structured physical activity, and in some cases GLP-1 receptor agonists such as semaglutide — have the best evidence for maintaining weight loss over time.

Physical Activity and Mortality Risk

Regular physical activity is independently associated with reduced all-cause mortality in people with type 2 diabetes, over and above its effects on weight, blood glucose, and blood pressure.

Meta-analyses of cohort studies consistently find that regular physical activity reduces all-cause mortality risk in people with T2D by approximately 30–40% compared with sedentary individuals (Source: Codella R, et al., Nutrients, 2021). The ADA recommends at least 150 minutes of moderate-intensity aerobic activity per week for most adults with type 2 diabetes.

Exercise improves all four CDC life expectancy factors simultaneously:

• Reduces BMI and waist circumference
• Improves HbA1c by up to 0.5–1.5 percentage points (systematic review evidence)
• Reduces systolic blood pressure by approximately 3–5 mmHg
• Modestly improves HDL and may reduce LDL

This makes physical activity uniquely powerful for longevity in type 2 diabetes — it hits every major risk factor at once. Walking, cycling, swimming, and resistance training all contribute.

Complications That Shorten Life — and How to Prevent Them

Life expectancy in type 2 diabetes is ultimately determined by whether serious complications develop, and if so, when and how severely. The main life-limiting complications are:

Cardiovascular disease (heart attack, stroke, heart failure): The most common cause of premature death in T2D. Prevented through blood pressure control, LDL-lowering (statins), smoking cessation, aspirin when appropriate, and — increasingly — SGLT-2 inhibitors and GLP-1 receptor agonists, which have demonstrated direct cardiovascular mortality benefits in large trials.

Chronic kidney disease: Progressive in many people with T2D; end-stage kidney failure carries a dramatically elevated mortality risk. Prevented through HbA1c control, blood pressure control, ACE inhibitors or ARBs, and monitored through annual eGFR and urine albumin testing.

Diabetic neuropathy and foot disease: Rarely directly lethal, but serious infections can lead to amputation, which itself carries high subsequent mortality. Prevented through blood glucose control and regular foot checks.

Retinopathy: Does not directly shorten life but is a marker of overall microvascular disease burden. Annual eye screening enables early treatment.

The message across all complications is the same: they are not inevitable. They develop on a timeline determined largely by how well blood glucose, blood pressure, and cholesterol are managed over years and decades.

The Optimistic Picture: Can You Live a Normal Lifespan?

Yes — for many people with type 2 diabetes, a near-normal lifespan is achievable, particularly those diagnosed later in life or who achieve strong early control.

Several developments in treatment have meaningfully improved outcomes since the original life expectancy estimates were made:

SGLT-2 inhibitors (empagliflozin, dapagliflozin, canagliflozin): Clinical trials including EMPA-REG OUTCOME have shown direct cardiovascular death reduction and kidney-protective effects that extend beyond blood glucose control (Source: Zinman B, et al., New England Journal of Medicine, 2015).

GLP-1 receptor agonists (semaglutide/Ozempic, liraglutide): The LEADER and SUSTAIN-6 trials showed significant reductions in major cardiovascular events and cardiovascular mortality in people with T2D at high cardiovascular risk (Source: Marso SP, et al., NEJM, 2016). Weight loss effects add further benefit.

These newer medication classes represent a substantial shift in what “optimal management” can achieve, and historical life expectancy figures may underestimate what people starting treatment today can expect.

For those who achieve type 2 diabetes remission through weight loss or intensive dietary change, the life expectancy trajectory may improve significantly — though ongoing monitoring remains essential. Research into diabetes reversal approaches is one of the most actively developing areas of T2D management.

Regular Check-ups: Your Annual Diabetes Review

The annual diabetes review is the mechanism through which life expectancy is protected. It typically includes:

• HbA1c — tracking blood glucose control over 3 months
• Blood pressure measurement — checking against target
• Lipid profile — LDL, HDL, and triglycerides
• eGFR and urine albumin:creatinine ratio — kidney function
• Eye screening — retinopathy check
• Foot examination — neuropathy and circulation
• Weight and BMI
• Medication review

Missing check-ups means missing the early signs of complications. Complications caught early are far more treatable than complications caught late.

Questions worth asking at your next review:

1. What is my 10-year cardiovascular risk? (QRISK3 in the UK; pooled cohort equations in the US)
2. Am I on the most appropriate medication for my cardiovascular and kidney risk profile?
3. Am I meeting my treatment targets — and if not, what should we change?

Frequently Asked Questions

What is the average life expectancy for someone with type 2 diabetes?
There is no single number that applies to everyone. At age 50, research suggests life expectancy is on average about 6 years shorter than for people without diabetes. But this varies significantly based on age at diagnosis, management quality, and whether complications develop. People diagnosed at 60 with no existing complications and good management may have near-normal life expectancy.

Does type 2 diabetes always shorten life?
Not necessarily. People who achieve excellent blood glucose control, maintain a healthy weight, control blood pressure and cholesterol, exercise regularly, and avoid smoking may live to average or above-average lifespans. The life expectancy reduction is not fixed — it is modifiable.

What is the most important thing to control for life expectancy?
According to CDC-highlighted research, weight (BMI) is the single most impactful factor, followed by HbA1c. However, cardiovascular risk — driven by blood pressure and cholesterol — causes the most deaths in T2D. Managing all four simultaneously provides the greatest life expectancy benefit.

Can type 2 diabetes go into remission?
Yes. Studies including the DiRECT trial show that significant weight loss (15 kg or more) can put T2D into remission — meaning blood glucose returns to normal without medication. However, the underlying susceptibility remains, and ongoing monitoring is necessary. See our full guide on whether type 2 diabetes can be reversed.

What medications help most with life expectancy in type 2 diabetes?
Beyond standard medications like metformin, the strongest evidence for extending life expectancy comes from SGLT-2 inhibitors (empagliflozin, dapagliflozin) and GLP-1 receptor agonists (semaglutide, liraglutide) in people at high cardiovascular risk. These have demonstrated direct reductions in cardiovascular death and kidney disease progression in clinical trials. Discuss with your doctor whether these are appropriate for you.

The Bottom Line

Type 2 diabetes is associated with a real reduction in life expectancy — typically 6–10 years on average depending on age at diagnosis. But several key messages emerge from the best available evidence:

• The reduction is not fixed. Meeting treatment targets for weight, HbA1c, blood pressure, and cholesterol can add 3 years for the average person, and more than 10 years for those with the highest risk levels.
• Age at diagnosis matters. Younger diagnosis means more cumulative exposure; earlier and more intensive management from the outset matters more.
• Weight loss is the most powerful single lever. BMI reduction provides the greatest life expectancy gain of any single treatment target.
• Complications, not diabetes itself, typically shorten life. Cardiovascular disease, kidney disease, and their prevention are the focus of modern diabetes management.
• Newer medications have changed the picture. SGLT-2 inhibitors and GLP-1 agonists provide cardiovascular and kidney benefits beyond glucose control, improving the outlook for people at high risk.
• Annual reviews are non-negotiable. Consistent monitoring catches complications early when they are most treatable.

For more on the lifestyle and dietary strategies that support longevity with T2D, see our guide on how to lower A1c naturally and the Diabetes Food List for a complete eating framework.

Medical content reviewed against guidance from the CDC, NHS, ADA, and peer-reviewed journals. Last reviewed: October 2026. ⚠️ Owner action: Add a named medical reviewer with credential (e.g., “Reviewed by [Name], Certified Diabetes Educator”) to this byline to comply with HW-5 authorship guidelines.

Sources

1. Kianmehr H, Zhang P, Luo J, et al. Potential Gains in Life Expectancy Associated With Achieving Treatment Goals in US Adults With Type 2 Diabetes. JAMA Network Open. 2022;5(4):e227705.
2. Centers for Disease Control and Prevention. How People with Type 2 Diabetes Can Live Longer. Updated May 2024.
3. Emerging Risk Factors Collaboration. Life expectancy associated with different ages at diagnosis of type 2 diabetes in high-income countries. The Lancet Diabetes & Endocrinology. 2023;11(10):731–742.
4. Stevens RJ, et al. Development of life-expectancy tables for people with type 2 diabetes. European Heart Journal. 2004; UKPDS Outcomes Model. PMC2663724.
5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment. The Lancet. 1998;352(9131):837–853.
6. Lean MEJ, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT). The Lancet. 2018;391(10120):541–551.
7. Zinman B, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (EMPA-REG OUTCOME). New England Journal of Medicine. 2015;373:2117–2128.
8. Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine. 2016;375:1834–1844.
9. Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease. The Lancet. 2010;375(9733):2215–2222.
10. Codella R, et al. Exercise in type 2 diabetes: metabolic effects and effects on body composition. Nutrients. 2021;13(12):4383.
11. National Health Service UK. Type 2 diabetes — complications. Accessed October 2026.
12. American Diabetes Association. Standards of Medical Care in Diabetes — 2024. Diabetes Care. 2024;47(Suppl 1).